>>> Intrepid Potash(IPI) - Intrepid Potash: Cowen views mine suspension as negat

Intrepid Potash: Cowen views mine suspension as negative for IPI shares and slightly positive for potash producing peers AGU, POT and MOS

Cowen notes that yesterday, after the close, IPI announced it received an imminent danger order which required the company's West Mine in New Mexico to shut down. The firm notes that this is IPI's largest mine and represents over 40% of production capacity. The firm is not surprised by maintenance issues given the age of IPI's mine operations and view the news as negative for IPI shares and slightly positive for potash producing peers AGU, POT and MOS.


--> No pre market indications for IPI for now

>>> GoPro estimates trimmed at Stifel following --> -6% Pre open

GoPro estimates trimmed at Stifel following AMBA guidance/commentary

Stifel notes that while anticipated in AMBA results (3Q revenue guide in line with consensus), Ambarella commentary around timing of wearable camera product launches strongly suggests that there is a low probability that an additional GoPro camera based on an Ambarella platform will launch before year-end. Considering both 1) the challenging anniversary of the sell-in of the HERO4 line in early 4Q a year ago and 2) the firm's impressions that the HERO+ LCD and HERO4 Session have been well received but aren't necessarily driving the category to new levels, they are taking a more conservative view on 4Q and 2016 estimates. Firm cuts FY4Q estimates from $767.2 mln and $1.04 to $710.1 mln and $0.92 (consensus of $728 mln and $0.94).
  • GPRO shares are lower by 6% at 41.17 in the pre-market.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance: NAV -15%, AMBA -10.7%, RADA -5.9%, AVAV -5.9%, GWRE -4%

M&A news: HTWR -12% (to acquire Valtech Cardio; also downgraded to Mkt Perform at Raymond James)

Select oil/gas related names showing early weakness with WTI down 1.5% today: SDRL -4.1%, RIG -2.3%, BP -1.7%, TOT -1.2%, RDS.A -1.1%

Other news: RJET -27.4% (may be nearing bankruptcy after the Teamsters union decided against overturning a local union decision blocking a pilot vote, according to reports), DGLY -13.6% (following Taser (TASR) press release indicating the USPTO has rejected 20 claims of a patent assigned to Digital Ally ), GPRO -6.3% (in sympathy with AMBA)

Analyst comments: TEF -1.2% (downgraded to Underperform at BofA/Merrill
)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance: VRA +19.8%, PRGN +8.7%, HRB +7.1%, (announces bank divestiture transaction now closed; announces new a $3.5 billion share repurchase program, modified Dutch auction), GIII +4.6%, QIHU +3.9%, BOBE +0.7%

M&A news: SURG +49.2% (to be acquired by Valeant Pharmaceuticals (VRX) for $6.50 per share in cash)

Select metals/producers trading higher: CAS +10.3%, BHP +2.4%, X +2%, RIO +1.9%, FCX +1.7%, AA +1.5%

Other news: ETRM +43.4% (announces that analyses of the ReCharge Study demonstrated Excess Weight Loss of 34% and significant improvements in obesity-related risk factors for vBloc Therapy treated, moderately obese patients who had at least one comorbidity), BVXV +37.5% (announces the intention of the NIAID, to launch a Phase 2 trial of its Multimeric-001 vaccine), ASTI+28.6% (still checking; stock closed at $0.21 yday), FLXN +15.8% ( announces FDA fast track designation for its FX006 candidate), WMGI +11.3% ( announces FDA approval for its Premarket Approval Application of its Augment Bone Graft), LOXO +7.3% (granted orphan drug designation by the FDA for LOXO-101 for treatment of patients with soft tissue sarcoma), TRVN +7.2% (cont strength), PBMD +4.7% (cont strength), TSRO +3.9% (FDA approval for Varubi), SUNE +3.8% (cont strength), TASR +3.6% (USPTO has rejected 20 claims of a patent assigned to Digital Ally (DGLY)), AZN +2.2% (enters license agreement to develop FluMist in Japan), XGTI +1.9% (announces the commercial availability of its xMax NOW transportable broadband wireless system), TSLA+1.8% (rebounding with broader mkt), JCP +1.7% (cont strength), GSK +1.6% (Nikkei Asian Review discusses that GlaxoSmithKline (GSK) Hep C vaccine supplies may have been impacted by explosion in China), BABA +1.4% (rebounding with broader mkt), SGMO +1.3% (Sangamo BioSci and Shire plc (SHPG) revise their collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease), ALU +1.2% (still checking), CELG +1.1% (favorable commentary on Monday's Mad Money), AMGN +1% (Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide), GM +1% (rebounding with broader mkt)

Analyst comments: CVEO +7.5% (upgraded to Buy at Sterne Agee CRT ), WIX +7% (upgraded to Buy at Deutsche Bank ), ARMH +3.1% (upgraded to Neutral at JP Morgan), PHG +1.9% (upgraded to Outperform at RBC Capital Mkts), WYNN +1.9% (upgraded to Buy at Credit Agricole), GIS +1.6% (upgraded to Equal-Weight at Morgan Stanley), TXT +1.4% (upgraded to Buy at Citigroup),T +1.4% (upgraded to Buy from Neutral at Citigroup), PYPL +1.2% (initiated with a Buy and $42 price target at Argus), DIS +1% (initiated with a Outperform at Credit Agricole
)

>>> US Early premarket gappers

Early premarket gappers
Gapping up: ETRM +36%, FLXN +15%, PBMD +13.4%, WMGI +10.4%, LOXO +9.8%, PRGN +8.7%, HRB +6.3%, GIII +4.6%, TJX +3%, ARMH +2.6%, RIO +2.5%, BHP +2.3%, SUNE +2.2%, FCX +1.8%, TSLA +1.8%, GSK +1.7%, T +1.6%, ALU +1.5%, BABA +1.5%, GM +1.5%, AZN +1.5%, CELG +1.3%, X +1.3%, AA +1.3%, JCP +1.3%, BAC +1%
Gapping down: AMBA -9.6%, GPRO -6.6%, RADA -5.9%, AVAV -5.9%, GWRE -5%, SDRL -4.8%, GFI -3%, RIG -2.3%, NBG -1.6%, BP -1.2%, RDS.A -1.2%, AU -0.9%, TOT -0.8%